Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

NCT06928584 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

221

Enrollment

OTHER

Sponsor class

Conditions

Locally Recurrent Rectal Cancer

Interventions

RADIATION: Conventional Radiotherapy
DRUG: Capecitabine
DRUG: 5-fluorouracil
DRUG: folinic acid
DRUG: Oxaliplatin
DRUG: Irinotecan
DRUG: Cetuximab
DRUG: Bevacizumab
RADIATION: Hypofractionated radiotherapy
DRUG: PD-1 antibody

Sponsor

Fudan University